Long-term Efficacy and Safety of Ponesimod, an oral S1P1 Receptor Modulator: Results from Randomized Phase II Core and Extension Studies in Relapsing-Remitting Multiple Sclerosis (1752)

• DOI: 10.1212/wnl.94.15_supplement.1752
• Publication Date: 2023-12-07T05:28:50Z
• Authors: Mark S. Freedman; Carlo Pozzilli; Eva Kubala Havrdova; Patricia K. Coyle; Alexandre Lemle; Michel Burcklen; Anna Larbalestier; Brian Hennessy; Tatiana Scherz; Andrea Vaclavkova; Tomas Olsson

Evaluate the long-term efficacy and safety of ponesimod in patients with relapsing-remitting multiple sclerosis (RRMS).